Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
Link to News Release: http://finance.yahoo.com/news/Oramed-Pharmaceuticals-Forms-prnews-1919477739.html?x=0&.v=1
Oramed Pharmaceuticals Inc. (OTCBB:ORMP.ob - News), a developer of oral drug delivery systems, announced today that its subsidiary Oramed Ltd. entered into a joint venture agreement with Laser Detect Systems Ltd. ("Laser Detect"), an Israeli company listed on the Tel Aviv Stock Exchange, for the establishment of a new company to be called Entera Bio Ltd. ("Entera"). Under the terms of the agreement, Oramed will out-license technology to Entera for the development of oral delivery drugs for certain indications. The out-licensed technology differs from Oramed's main delivery technology that is used for oral insulin and is subject to a different patent application. Entera's initial development effort will be an oral formulation for the treatment of osteoporosis.
Dr. Phillip Schwartz will serve as Entera's Chief Executive Officer. Dr. Schwartz has over 10 years of experience in the pharmaceutical and biotech industries and served as a lecturer at Harvard Medical School. Prior to joining Entera, Dr. Schwartz served as the Scientific and Medical Development Manager for Endo Pharmaceuticals (NasdaqGS:ENDP - News).
Nadav Kidron, Chief Executive Officer of Oramed Pharmaceuticals, commented, "This joint venture affords an opportunity to explore a technology with different characteristics from Oramed's main technology, which has the potential to make a significant contribution in the oral drug delivery arena. We look forward to a successful relationship with Laser Detect and Entera."
According to the agreement, Laser Detect will invest $600,000 in Entera, and Entera will be owned in equal parts by Oramed and Laser Detect. Entera's Chief Executive Officer will be granted options to purchase ordinary shares of Entera, reflecting 9.9% of the Entera's share capital, immediately following the dilution by these options. Entera's board of directors will be comprised of four members - one director designated by each of Oramed and Laser Detect, Dr. Schwartz and Mr. Kenneth Abramowitz, co-founder and Managing General Partner of NGN Capital.
Mr. Zeev Bronfeld, who is one of Laser Detect's controlling shareholders, is also an affiliated shareholder of Oramed Pharmaceuticals Inc. Accordingly, the closing of the transaction is subject to the approval of Laser Detect's shareholders.
For more information about Oramed's clinical development programs, please visit http://www.oramed.com.
Safe Harbor Statement
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risk that the transaction will not be approved by the shareholders of Laser Detect, the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; Entera's ability to obtain additional funding required to conduct its research, development and commercialization activities; and Oramed's ability to maintain a significant equity stake in Entera. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, 91390, Israel
Emerging Markets Consulting, LLC.
EMC and/or its principals, affiliates and representatives receive cash and/or compensation in the Securities in connection with preparation and dissemination of the Corporate Information. EMC did not pay cash consideration for the Securities that it holds (other than payments that may be made by EMC to the Profiled Companies for the exercise of warrants), and any of the Securities held by EMC were issued in exchange for EMC’s services. Because EMC is a Shareholder of the Profiled Companies, EMC may have a conflict of interest with the Recipients as well as the Profiled Companies. Independent of any compensation that EMC and/or its principals, affiliates, and representatives may receive, EMC and/or its principals, affiliates, and representatives may at any time purchase and/or sell the Securities, including simultaneous with the publication or distribution of the Corporate Information. The buying and selling of the Securities by EMC and/or its principals, affiliates, and representatives may negatively effect the price of the Securities or cause the price of the securities to increase or decrease or become unstable.
EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Companies or the Securities, and has not conducted due diligence of any data or information contained in the Corporate Information. The Corporate Information is based solely upon data and information provided by the Profiled Companies and EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Corporate Information. EMC conducts no due diligence of any type of the Profiled Companies or the Securities. Recipients should not rely on the data or information contained in the Corporate Information in making an investment decision and should conduct their own research of the Profiled Companies. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Corporate Information. Each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Companies or the Securities.
EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Corporate Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities. The Securities may be thinly traded and not listed on any national securities exchange and involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission's penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities. An investment in the Securities could result in the loss of some or all of an investment.
Recipients should (with the assistance of their legal and financial advisors) review Securities and Exchange Commission (“SEC”) filings regarding the Profiled Companies that are SEC reporting issuers. These SEC filings are available for review at www.sec.gov. Recipients should review investment guides that are available at the same SEC website and the National Association of Security Dealers website at www.nasd.com.
Statements contained in the Corporate Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as “believes”, “expects”, “may”, “will”, or “should”, or “anticipates”. Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Corporate Information. The actual results of a Profiled Company’s operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information.
The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Companies to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Companies. Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Companies’ securities, (ii) shareholder voting power; and (iii) each shareholder’s proportionate ownership of any Profiled Company.
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below:
Disclaimer EMC has a December 16, 2009 contract to provide Investor Relations services for Oramed Pharmaceuticals for a six month period. The company is to pay EMC 100,000 restricted shares of Stock and $5,000 monthly. EMC has been paid $35,000 and 100,000 restricted shares. View full disclaimer at http://server1.streamsend.com/streamsend/clicktracker.php?cd=5119&ld=2&md=209&ud=abc90c6eee3041cdd572857428e5a03f&url=http://www.emergingmarketsllc.com/disclaimer.php